Premaitha Health said that Yourgene Bioscience, acquired in March 2017, was now firmly established as one of India's leading providers in the emerging non-invasive prenatal testing (NIPT) market.
It had representation in nine of the 15 most populous states, and several of the largest nationwide pathology laboratory groups were running Yourgene's NIPT workflow in-house.
There were five laboratories with installed NIPT solutions, and an additional two laboratories were expected to become active later this year.
"These laboratories have an extensive network of hospitals feeding samples into them across all the regions of the country," the company said.
"In addition, there are currently thirteen Indian laboratory customers sending samples to Yourgene's laboratory in Taiwan for processing and analysis and the expectation is that some of these laboratories in time will establish their NIPT solution in house."
NIPT in India was still in an early phase of development and Yourgene's test volumes were growing at a rate of 100% a year with coverage across all key metropolitan areas including Mumbai, New Delhi, Bangalore, Hyderabad and Chennai.
"India has the highest birth rate in the world with over 26 million births per annum, and access to prenatal screening is spreading to the expanding middle class populations living in the cities and regions where screening is available. Yourgene's menu-based test offering allows for testing to be tailored to local ethical and clinical requirements."
At 9:54am: (LON:NIPT) Premaitha Health Plc share price was +0.38p at 10p